AIPAC

The Financial Services Innovation Coalition (FSIC) Launches its Minority Policy Priority Task Force

Retrieved on: 
Wednesday, February 28, 2024
Chairperson, African Americans, ALL, All-America, Government, Policy, Task force, Community, AIPAC

WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The formation of the Minority Policy Priority Task Force (MPPTF) by the Financial Services Innovation Coalition (FSIC) marks a strategic move towards empowering African American and other minority groups in the political arena.

Key Points: 
  • WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The formation of the Minority Policy Priority Task Force (MPPTF) by the Financial Services Innovation Coalition (FSIC) marks a strategic move towards empowering African American and other minority groups in the political arena.
  • Peter J. Spann, Co-Chair of the Minority Policy Priority Task Force.
  • "We're here to reclaim our power in policymaking, to ensure our communities' needs lead the conversation, not follow it," stated Brad Anderson, Co-chair of the Minority Policy Priority Task Force.
  • FSIC believes that with improved economic opportunities in minority and underserved communities, the economy will improve significantly and benefit ALL Americans.

This Week in Policy & Public Interest News: 11 Stories You Need to See

Retrieved on: 
Friday, December 8, 2023
Holiday, Pet, Hostage, Organization, ADL, Employment, Policy, Climate change, AJC, UN, Risk, WFP, Database, Tesfaye, ADP, Conference, Malcolm Hoenlein, Housing, American Jewish Committee, Collegiate summer baseball, Growth, PR Newswire, Starvation, Letter, JFNA, Restaurant, AIPAC, Face, Accuracy and precision, Education, Mobile phone, Renewable energy

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the policy and public interest industries stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • A roundup of the week's most newsworthy policy and public interest press releases from PR Newswire, including holiday hazards for pets and those celebrating with alcohol.
  • To help journalists covering the policy and public interest industries stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.
  • The list below includes the headline (with a link to the full text) and an excerpt from each story.
  • The letter emphasizes the need for an inclusive and cooperative negotiation process and urges leaders to prioritize climate education globally.

LEADING U.S. JEWISH ORGANIZATIONS LAUNCH 'THE 10/7 PROJECT,' A NEW CENTRALIZED COMMUNICATIONS OPERATION TO PROMOTE CONTINUED U.S. BIPARTISAN SUPPORT FOR ISRAEL; PUSH FOR ACCURATE, COMPLETE COVERAGE OF ISRAEL-HAMAS WAR; STRONGER FOCUS ON OCT. 7 VICTIMS AND

Retrieved on: 
Tuesday, December 5, 2023
Hamas, Organization, ADL, Violence, National Mall, The Holocaust, AJC, Americas (terminology), Jews, Multimedia, Trust, Mall, Social media, Conference, Malcolm Hoenlein, American Jewish Committee, Collegiate summer baseball, JFNA, AIPAC, Face, American Jews, Mobile phone, Nursing

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Following last month's historic March for Israel that brought nearly 300,000 people to the National Mall, the nation's most prominent American Jewish organizations have today joined forces to launch The 10/7 Project — a new centralized communications operation. The 10/7 Project is designed to promote continued U.S. bipartisan support for Israel by working to ensure more complete and accurate information about the Israel-Hamas war in real time for policymakers and the American public.

Key Points: 
  • The 10/7 Project is designed to promote continued U.S. bipartisan support for Israel by working to ensure more complete and accurate information about the Israel-Hamas war in real time for policymakers and the American public.
  • "Tragically, we have even seen alarming incidents of antisemitic violence and hate stemming from inaccurate coverage of the conflict.
  • "The United States must continue to stand with our democratic ally as it works to protect its families and secure its future."
  • The 10/7 Project has also launched a daily newsletter, The 10/7 Project Daybook, for journalists and other interested parties and a new website .

LEADING U.S. JEWISH ORGANIZATIONS LAUNCH 'THE 10/7 PROJECT,' A NEW CENTRALIZED COMMUNICATIONS OPERATION TO PROMOTE CONTINUED U.S. BIPARTISAN SUPPORT FOR ISRAEL; PUSH FOR ACCURATE, COMPLETE COVERAGE OF ISRAEL-HAMAS WAR; STRONGER FOCUS ON OCT. 7 VICTIMS AND

Retrieved on: 
Tuesday, December 5, 2023
Hamas, Organization, ADL, Violence, National Mall, The Holocaust, AJC, Americas (terminology), Jews, Trust, Mall, Social media, Conference, Malcolm Hoenlein, American Jewish Committee, Collegiate summer baseball, JFNA, AIPAC, Face, American Jews, Mobile phone, Nursing

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- Following last month's historic March for Israel that brought nearly 300,000 people to the National Mall, the nation's most prominent American Jewish organizations have today joined forces to launch The 10/7 Project — a new centralized communications operation. The 10/7 Project is designed to promote continued U.S. bipartisan support for Israel by working to ensure more complete and accurate information about the Israel-Hamas war in real time for policymakers and the American public.

Key Points: 
  • The 10/7 Project is designed to promote continued U.S. bipartisan support for Israel by working to ensure more complete and accurate information about the Israel-Hamas war in real time for policymakers and the American public.
  • "Tragically, we have even seen alarming incidents of antisemitic violence and hate stemming from inaccurate coverage of the conflict.
  • "The United States must continue to stand with our democratic ally as it works to protect its families and secure its future."
  • The 10/7 Project has also launched a daily newsletter, The 10/7 Project Daybook, for journalists and other interested parties and a new website .

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Retrieved on: 
Friday, November 3, 2023
ASX, MHC, PD-L1, NSCLC, Gamma ray, Poster, ESMO, Progression-free survival, Biomarker, TPS, RNA, Society for Immunotherapy of Cancer, Pembrolizumab, GEP, AIPAC, Merck, CD8, SITC, T cell, Immunotherapy, Paclitaxel, Immune system, Annual general meeting, ALC, Blood, Autoimmune disease, Serum, Gene, Lung cancer, CXCL10, Lymphocyte, IMM, Cancer, Society, Monocyte, Patient, Merck & Co., Vaccine, Medical imaging, Pharmaceutical industry, LAG-3

SYDNEY, AUSTRALIA, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial evaluating eftilagimod alpha (“efti”), a soluble LAG-3 protein and first-in-class MHC Class II agonist administered subcutaneously, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment for patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Dr Frederic Triebel, Immutep CSO, said, “Immunomonitoring of blood cells is of prime importance when one would like to understand the effect of a systemic immunostimulant injected subcutaneously, like efti is.
  • Importantly, the pharmacodynamic data from efti in combination with pembrolizumab is associated with the 35.5-month median Overall Survival in first-line treatment of metastastic non-small cell lung cancer patients expressing PD-L1 (TPS >1%) that we recently reported at ESMO 2023.
  • This biomarker data from the TACTI-002 Phase II is similar to the biomarker analysis from Immutep’s randomized, double-blind AIPAC Phase IIb trial in HER2-/HR+ metastatic breast cancer, which combined efti solely with paclitaxel chemotherapy and did not include any anti-PD-1 therapy.
  • The poster titled “Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab” will be available on the Posters & Publications section of Immutep’s website.

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Retrieved on: 
Thursday, May 25, 2023
AIPAC, Survival, MHC, Cancer, Paclitaxel, ASX, IMM, HIV disease progression rates, Patient, Autoimmune disease, Immutep, Phase, III, Safety, Pharmaceutical industry

SYDNEY, AUSTRALIA, May 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed at a European clinical site for its integrated Phase II/III AIPAC-003 trial in metastatic breast cancer.

Key Points: 
  • AIPAC-003 is evaluating eftilagimod alpha (“efti”), Immutep’s soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with standard-of-care paclitaxel for the treatment of metastatic HER2-neg/low breast cancer and triple-negative breast cancer.
  • Immutep CSO, Prof Frédéric Triebel said: “Commencing patient dosing for our AIPAC-003 trial of efti is a significant milestone for Immutep.
  • Depending on the Phase II results, potential regulatory actions and resources, a randomized, double-blinded, placebo-controlled Phase III portion will then follow.
  • The Phase III will have overall survival as the primary objective and may include a specific patient population.

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

Retrieved on: 
Tuesday, March 14, 2023
AIPAC, EMA, Cancer, Monocyte, Glomus tumor, Breast cancer, MHC, Science, CD8, Paclitaxel, IRB, Survival, Active immunotherapy, IMM, Institutional review board, MHC class II, OS, Marketing Authorisation Application, Phase, IO, MAA, Autoimmune disease, APC, Patient, MOS, Triple-negative breast cancer, B cell, FDA, US Foods, NSCLC, TNBC, European Medicines Agency, MBC, ORR, Calendar, BLA, Quality of life, Safety, HNSCC, Food, Biologics license application, ASX, HIV disease progression rates, Pharmaceutical industry

SYDNEY, AUSTRALIA, March 14, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC). Regulatory approval has been received in the US and Institutional Review Board (IRB) approval has been received in Spain, with approvals in additional countries anticipated to follow shortly. The first patient is expected to be enrolled in early Q2 CY2023.

Key Points: 
  • As a first-in-class soluble LAG-3 protein targeting MHC Class II ligands on antigen-presenting cells (APC), efti is uniquely positioned to improve clinical outcomes from standard-of-care chemotherapy.
  • Based on feedback from the FDA/EMA, the HR+/HER2-neg/low MBC patient population has been expanded to include triple-negative breast cancer (TNBC), an aggressive cancer with limited treatment options, which together account for ~78% of breast cancer cases.
  • Depending on the Phase II results, potential regulatory actions and resources, a randomized, double-blinded, placebo-controlled Phase III portion will then follow.
  • The Phase III will have overall survival as the primary objective and may include a specific patient population.

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

Retrieved on: 
Friday, December 23, 2022
Cancer, Antigen, Immutep, Calendar, CMO, Autoimmune disease, ASX, Optimus, BLA, TNBC, HIV disease progression rates, Breast cancer, IMM, MBC, Patient, Overalls, US Foods, Paclitaxel, Safety, AIPAC, FDA, B cell, Triple-negative breast cancer, Immune system, Phase, Quality of life, EMA, NSCLC, Survival, Biologics license application, Pharmaceutical industry

The Company and the FDA have agreed to an integrated Phase II/III trial design that will help inform a Biologics License Application (BLA).

Key Points: 
  • The Company and the FDA have agreed to an integrated Phase II/III trial design that will help inform a Biologics License Application (BLA).
  • Based on the encouraging efficacy, favourable safety, and learnings from the randomised AIPAC Phase IIb trial, which administered efti and chemotherapy on different days and ceased chemotherapy at six months, patients will receive efti and paclitaxel on the same day and treatment will continue until disease progression.
  • The patient population has also been expanded to include triple-negative breast cancer (TNBC), an aggressive form of breast cancer with limited treatment options.
  • Our engagement with regulatory agencies to establish the optimal design of a registrational trial has steadily progressed during the year and we are pleased with the FDA’s positive feedback during this follow up meeting.

SKLAR KIRSH'S ANDREW KIRSH NAMED TOP REAL ESTATE LAWYER IN CALIFORNIA

Retrieved on: 
Thursday, December 8, 2022
Make-A-Wish Foundation, The Leadership Council, Northwestern University, American Israel Public Affairs Committee, AIPAC, Daily Journal Corporation, Lawyer, Jewish Federation, Bankruptcy, Federation, Young Presidents' Organization, Jewish Leadership Council, Real estate

LOS ANGELES, Dec. 8, 2022 /PRNewswire/ -- Los Angeles-based law boutique Sklar Kirsh LLP announced today that its Co-Chairman Andrew Kirsh has been recognized by Connect Media Commercial Real Estate in its "2022 Lawyers in Real Estate Awards" for the California region. According to the publication, the award spotlights ten attorneys nationally and from each of the ten areas covered by their regional newsletters who excel in their practices as well as their contributions to the community.

Key Points: 
  • LOS ANGELES, Dec. 8, 2022 /PRNewswire/ --Los Angeles-based law boutique Sklar Kirsh LLP announced today that its Co-Chairman Andrew Kirsh has been recognized by Connect Media Commercial Real Estate in its "2022 Lawyers in Real Estate Awards" for the California region .
  • "Andrew leads a group of talented, real estate transactional attorneys whose 2022 dealflow includes 130 closings and $5 billion in transactional volume across 19 states," said fellow Co-Chairman Jeffrey Sklar .
  • Kirsh's additional, recent accolades include being named a Best Lawyer in America, a "Commercial Real Estate Visionary" by Commercial Real Estate Magazine, a Southern California Super Lawyer and a "Top 40 Real Estate Lawyer" by the Los Angeles Business Journal.
  • Sklar Kirsh LLP is a boutique law firm that provides sophisticated and expert advice in the areas of corporate, real estate, bankruptcy, and entertainment law as well as commercial, real estate and entertainment litigation.

Steven P. Rosenthal Gives a Second $1 Million to Support Innovation at Northeast Arc

Retrieved on: 
Tuesday, November 22, 2022
General Health, Fund Raising, Health, Foundation, Philanthropy, Trustee, Habilitation, Family support, Robert Rosenthal (businessman), Massachusetts Convention Center Authority, Multimedia, Liberty Tree Mall, Swedish National Board of Institutional Care, Ruderman Family Foundation, Black box theater, Acquisition, Disability, Rosenthal, Gold, State Employment Service (Azerbaijan), AIPAC, Transition, Loomis, City, Harvard College, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, Heart, Risk, Boston University, Richard P. Rosenthal, Pharmaceutical industry, Management, Recreation

Boston businessman, Steven P. Rosenthal , Chairman of West Shore , has pledged $1 million to Northeast Arc in support of its Changing Lives Fund.

Key Points: 
  • Boston businessman, Steven P. Rosenthal , Chairman of West Shore , has pledged $1 million to Northeast Arc in support of its Changing Lives Fund.
  • Pictured from left: J.J.s father John Millard, J.J., his mother Joanna Millard, Rosenthal and Jo Ann Simons, President & CEO Northeast Arc.
  • He hopes the new gift will continue to encourage others to support Northeast Arc as well.
  • When Steve made his initial $1 million donation it was a real game-changer for us, said Jo Ann Simons , President and CEO of Northeast Arc.